SURPASS-CVOT: A comparison of Tirzepatide and Dulaglutide

In this weeks episode of Diabetes Insights - Breakthroughs and Innovators, experts discuss the highly anticipated SURPASS CVOT trial, a head-to-head cardiovascular outcomes study comparing tirzepatide 15 mg weekly with dulaglutide 1.5 mg weekly in people with type 2 diabetes. With over 13,000 participants, the trial demonstrates that tirzepatide provides equivalent cardioprotective benefits to dulaglutide, confirming its role in improving both glycaemic control and cardiovascular outcomes. EASD TV Host Vivienne Parry sits with Prof. Tina Vilsbøll (EASD Honorary Secretary) and Prof. Hertzel Gerstein (EASD Independent Advisor and McMaster University) to unpack the trial’s implications for clinical practice, highlighting how outcomes trials like this inform personalised medicine, integrate care between diabetologists and cardiologists, and generate new hypotheses in areas such as liver disease, cognitive function, and obesity management. This episode underscores the growing importance of transdisciplinary approaches in diabetes care, where therapies can target multiple complications simultaneously. Join us to understand how outcomes trials like SURPASS-CVOT are shaping guidelines, expanding treatment options, and improving care for people living with type 2 diabetes worldwide.